ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 6

Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

, , , ,

This episode discusses the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted targeted treatments, comparing the clinical benefits of a targeted ADC approach vs chemotherapy, with a focus on the TROPION-Lung01 study of Dato-DXd vs docetaxel for heavily pretreated advanced/metastatic NSCLC with actionable genomic alterations.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC
    EP. 2: Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA
    EP. 3: ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC
    EP. 4: Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations
    EP. 5: Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC
    Now Viewing
    EP. 6: Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges
    EP. 7: Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01
    EP. 8: Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies
    EP. 9: Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC
    EP. 10: Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC
    EP. 11: Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd
    EP. 12: Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice
    EP. 13: HERTHENA-Lung02 Trial: Exploring the Role of Patritumab Deruxtecan in Advanced EGFR-Mutant NSCLC
    EP. 14: Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02
    EP. 15: Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

    Video content above is prompted by the following:

    • Please briefly discuss the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted available, targeted therapies.
    • What are the clinical benefits of a targeted ADC approach vs chemotherapy for heavily pretreated advanced/metastatic NSCLC?
    x